France· FR:68503549
CHLORHYDRATE D'OXYBUPROCAINE THEA 1,6 mg/0,4 ml, collyre en récipient unidose
A medicinal product containing chlorhydrate d'oxybuprocaïne, registered in France by THEA.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- CHLORHYDRATE D'OXYBUPROCAÏNE
- Manufacturer
- THEA
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 2
- cip13340093657686520 récipient(s) unidose(s) polyéthylène de 0,4 ml
- cip133400936576926100 récipient(s) unidose(s) polyéthylène de 0,4 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Chlorhydrate d'oxybuprocaïne in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandMinims Oxybuprocaine HydrochlorideBausch + Lomb Ireland Limited
- SwedenObupro 4 mg/ml Ögondroppar, lösningAgepha Pharma s.r.o.
- NetherlandsMinims Oxybuprocainehydrochloride 4 mg/ml, oogdruppels, oplossingBausch + Lomb Ireland Limited
- CzechiaBENOXIUNIMED PHARMA spol. s r.o., Bratislava
- PolandNovainAGEPHA Pharma s.r.o.
- IcelandNovainAgepha Pharma s.r.o.
- IrelandOxybuprocaine Agepha 4 mg/ml eye drops, solutionAGEPHA Pharma s.r.o.
- BelgiumMinims Oxybuprocaine Chlorhydrate 4 mg/mlBausch + Lomb Ireland
Authorised across Europe · EMA
The same active substance is authorised in 25 EEA countries. Names it is sold under:
- Austria · Benoxinat Zur Anästhesie In Der Oto-Rhino-Laryngologie, Novain
- Belgium · Minims Oxybuprocaine Chlorhydrate Bausch + Lomb Ireland Limited, Minims Oxybuprocaïnehydrochloride Bausch + Lomb Ireland Limited
- Bulgaria · Бенокси
- Czechia · Benoxi, Oxybuprocaine Olikla
- Germany · Conjuncain® Edo®, Novesine
- Denmark · Oftasen, Oxybuprocainhydrochlorid Agepha
- Estonia · Novain
- Spain · Oxibuprocaína Hidrocloruro Agepha
- Finland · Minims, Obupro 4 Mg/Ml Silmätipat, Liuos
- United Kingdom (Northern Ireland) · Oxybuprocaine Hydrochloride Alfa Intes
- Croatia · Ophtesia
- Hungary · Humacain, Oxybuprocaine Hydrochloride Agepha
- Ireland · Oxybuprocaine Agepha
- Iceland · Novain
- Italy · Benoxinato Cloridrato Intes, Novesina
- Lithuania · Novain
- Luxembourg · Conjuncain Edo, Minims
- Latvia · Oxybuprocaine Hydrochloride Agepha 4 Mg/Ml
- Netherlands · Minims, Monofree
- Norway · Obupro, Oxibuprokain Minims Bausch + Lomb Ireland Limited
- Poland · Novain, 4 Mg/Ml,
- Portugal · Anestocil, Novain 4 Mg/Ml Colírio,
- Romania · Benoxi, Oftacain
- Sweden · Novain, Oxibuprokain Bausch & Lomb
- Slovakia · Benoxi, Oxybuprocaine Olikla
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5a84be04-f060-4067-b0ee-3a3362400fc2 GET /v1/drugs/5a84be04-f060-4067-b0ee-3a3362400fc2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "68503549",
"date_amm": "1993-03-23",
"type_amm": "Procédure nationale",
"numero_ue": null,
"substance": "CHLORHYDRATE D'OXYBUPROCAÏNE",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "collyre",
"voies_administration": "ophtalmique",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Non"
}See everything about chlorhydrate d'oxybuprocaïne.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.